Gyre Therapeutics, Inc. Fair Value Adjustment of Warrants
Gyre Therapeutics, Inc. (GYRE) reported Fair Value Adjustment of Warrants of -$132.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-07
- Gyre Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$132.00K.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$89.00K.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$263.00K.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $23.00K, a 89.91% decline year-over-year.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for fiscal 2025 was -$2.71M.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for fiscal 2024 was -$7.17M, a 177.39% decline from fiscal 2023.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for fiscal 2023 was $9.26M.
- Gyre Therapeutics, Inc. fair value adjustment of warrants for fiscal 2015 was -$91.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$132.00K 10-Q · filed 2026-08-07 | -$220.00K 10-Q · filed 2026-08-07 | -$484.00K derived: sum of 3 quarters · filed 2026-08-07 | -$461.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | -$89.00K 10-Q · filed 2026-05-08 | -$352.00K derived: sum of 2 quarters · filed 2026-05-08 | -$329.00K derived: sum of 3 quarters · filed 2026-05-08 | -$541.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | -$263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$240.00K derived: sum of 2 quarters · filed 2026-03-13 | -$452.00K derived: sum of 3 quarters · filed 2026-08-07 | -$2.71M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $23.00K 10-Q · filed 2025-11-07 | -$189.00K derived: sum of 2 quarters · filed 2026-08-07 | -$2.44M 10-Q · filed 2025-11-07 | -$2.64M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | -$212.00K 10-Q · filed 2026-08-07 | -$2.47M 10-Q · filed 2026-08-07 | -$2.66M derived: sum of 3 quarters · filed 2026-08-07 | -$2.43M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | -$2.25M 10-Q · filed 2026-05-08 | -$2.45M derived: sum of 2 quarters · filed 2026-05-08 | -$2.22M derived: sum of 3 quarters · filed 2026-05-08 | -$5.13M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | -$194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $34.00K derived: sum of 2 quarters · filed 2026-03-13 | -$2.88M derived: sum of 3 quarters · filed 2026-03-13 | -$7.17M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $228.00K 10-Q · filed 2025-11-07 | -$2.69M derived: sum of 2 quarters · filed 2025-11-07 | -$6.97M 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | -$2.91M 10-Q · filed 2025-08-11 | -$7.20M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | -$4.29M 10-Q · filed 2025-05-09 | ||||
| 2023-12-31 | $9.26M 10-K · filed 2025-03-17 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $504.00K derived: sum of 2 quarters · filed 2017-03-08 | -$12.00K derived: sum of 3 quarters · filed 2017-03-08 | -$91.00K 10-K · filed 2017-03-08 | |
| 2015-09-30 | $504.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$12.00K derived: sum of 2 quarters · filed 2016-11-03 | -$91.00K 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | -$516.00K 8-K/A · filed 2015-10-23 | -$595.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$78.00K 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | -$354.00K 10-K · filed 2016-03-09 | -$354.52K 8-K/A · filed 2015-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |